The present invention relates to a method for prolonging half-life of a protein or a (poly)peptide by replacing one or more amino acid residues of the protein. Further, the present invention is about the protein having a prolonged half-life prepared by the method above.

Disclosed is a sheep PDGFD, nucleic acids encoding PDGFD and recombinant lentivirus, host cell and use thereof, which relate to the technical field of molecular cell biology. The sheep platelet-derived growth factor PDGFD includes one or two of PDGFD-T1 and PDGFD-T2. The amino acid sequence of PDGFD-T1 is set forth in SEQ ID NO:1, and the amino acid sequence of PDGFD-T2 is set forth in SEQ ID NO:2. PDGFD-T1 and PDGFD-T2 are able to significantly inhibit the differentiation and maturation of precursor adipocytes and significantly reduce the mRNA relative expression levels of adipogenic differentiation-related genes CEBPα, PPARγ, FAS, FABP4 and LPL, thereby inhibiting animal fat deposition and improving animal meat quality, and have important guiding significance in the fields of life science, medical science, animal husbandry and the like.

Disclosed is a sheep PDGFD, nucleic acids encoding PDGFD and recombinant lentivirus, host cell and use thereof, which relate to the technical field of molecular cell biology. The sheep platelet-derived growth factor PDGFD includes one or two of PDGFD-T1 and PDGFD-T2. The amino acid sequence of PDGFD-T1 is set forth in SEQ ID NO:1, and the amino acid sequence of PDGFD-T2 is set forth in SEQ ID NO:2. PDGFD-T1 and PDGFD-T2 are able to significantly inhibit the differentiation and maturation of precursor adipocytes and significantly reduce the mRNA relative expression levels of adipogenic differentiation-related genes CEBPα, PPARγ, FAS, FABP4 and LPL, thereby inhibiting animal fat deposition and improving animal meat quality, and have important guiding significance in the fields of life science, medical science, animal husbandry and the like.

Agents which inhibit Gads dimerization are provided. Accordingly there is provided an agent which inhibits Gads (SEQ ID NO: 1) dimerization, the agent interacting with a pharmacophore binding site comprising an amino acid selected from the group consisting of F55, P56, W58, F59, E61, G62, A84-F92, V107-N111, Y115, F116, L125 and N126 of SEQ ID NO: 1. Also provided an agent which inhibits Gads (SEQ ID NO: 1) dimerization, the agent interacting with a pharmacophore binding site comprising an amino acid sequence of an SH3 domain of SEQ ID NO: 1. Also provided are methods of inhibiting activation of a T cell and/or a mast cell and methods of treating or preventing a disease associated with activation of T cells or an allergic response.

Agents which inhibit Gads dimerization are provided. Accordingly there is provided an agent which inhibits Gads (SEQ ID NO: 1) dimerization, the agent interacting with a pharmacophore binding site comprising an amino acid selected from the group consisting of F55, P56, W58, F59, E61, G62, A84-F92, V107-N111, Y115, F116, L125 and N126 of SEQ ID NO: 1. Also provided an agent which inhibits Gads (SEQ ID NO: 1) dimerization, the agent interacting with a pharmacophore binding site comprising an amino acid sequence of an SH3 domain of SEQ ID NO: 1. Also provided are methods of inhibiting activation of a T cell and/or a mast cell and methods of treating or preventing a disease associated with activation of T cells or an allergic response.

Disclosed herein are compositions, methods, and systems for the purification and/or detection of recombinant and other proteins. In some embodiments, compositions may comprise recombinant protein with one or more sequences having substantial homology to RP-Tag Small or RP-Tag Large. In some cases, the disclosed compositions may be useful in binding or recognizing target proteins.

Disclosed herein are compositions, methods, and systems for the purification and/or detection of recombinant and other proteins. In some embodiments, compositions may comprise recombinant protein with one or more sequences having substantial homology to RP-Tag Small or RP-Tag Large. In some cases, the disclosed compositions may be useful in binding or recognizing target proteins.

A method for promoting growth of bone, periodontium, ligament, or cartilage in a mammal by applying to the bone, periodontium, ligament, or cartilage a composition comprising platelet-derived growth factor at a concentration in the range of about 0.1 mg/mL to about 1.0 mg/mL in a pharmaceutically acceptable liquid carrier and a pharmaceutically-acceptable solid carrier.

A method for promoting growth of bone, periodontium, ligament, or cartilage in a mammal by applying to the bone, periodontium, ligament, or cartilage a composition comprising platelet-derived growth factor at a concentration in the range of about 0.1 mg/mL to about 1.0 mg/mL in a pharmaceutically acceptable liquid carrier and a pharmaceutically-acceptable solid carrier.

A method for promoting growth of bone, periodontium, ligament, or cartilage in a mammal by applying to the bone, periodontium, ligament, or cartilage a composition comprising platelet-derived growth factor at a concentration in the range of about 0.1 mg/mL to about 1.0 mg/mL in a pharmaceutically acceptable liquid carrier and a pharmaceutically-acceptable solid carrier.